SCHEMBL20768403

SCHEMBL20768403

Cn1c(C(=O)NC2(c3ccccc3C(=O)O)CCCN(Cc3ccccc3)C2)cc2c(Cl)c(Cl)ccc21

nearest known ligand 0.52

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ PHGDH O43175 14/20 0.52
▸ SLC6A9 P48067 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CYP2D6 P10635 3/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20768410 0.86 PHGDH (0.55) PHGDHSLC6A9
SCHEMBL25153797 0.85 PHGDH (0.51) PHGDHSLC6A9KDM4EATMNPSR1
SCHEMBL19331263 0.84 PHGDH (0.50) PHGDHSLC6A9KDM4EATMNPSR1
SCHEMBL19343446 0.84 PHGDH (0.59) PHGDHSLC6A9KDM4EATMNPSR1
SCHEMBL26373069 0.83 PHGDH (0.49) PHGDHSLC6A9CYP2D6ALDH1A1
SCHEMBL19331274 0.82 PHGDH (0.48) PHGDHSLC6A9CYP2D6ALDH1A1CYP3A4
SCHEMBL19344079 0.81 PHGDH (0.46) PHGDHSLC6A9ALDH1A1
SCHEMBL19331000 0.77 PTGS2 (0.40) SLC6A9KDM4ECYP2D6ALDH1A1CYP3A4
SCHEMBL20768502 0.77 PHGDH (0.43) PHGDHKDM4EATMNPSR1CYP2D6
SCHEMBL20768510 0.75 PHGDH (0.49) PHGDHSLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3884939-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2023-04-25 — — US disclosed
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-01-12 — — US disclosed
EP-3884939-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2021-09-29 — — EP disclosed
EP-3426243-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2021-05-19 — — EP disclosed
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-03-23 — — US disclosed
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885KDM4E 2482/4885
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885KDM4E 2482/4885
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885KDM4E 2482/4885
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885KDM4E 2482/4885
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885KDM4E 2482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback